Management of a Fixed and Immobile Urethra

Treatment Options for Fixed/Immobile Urethra

The American Urological Association recommends pubovaginal sling (PVS), retropubic midurethral sling (RMUS), or urethral bulking agents as the preferred treatment options for patients with stress urinary incontinence (SUI) and a fixed, immobile urethra 1
Pubovaginal sling (PVS) is the preferred option for completely non-mobile urethras due to its ability to provide appropriate support without excessive tension 1
Retropubic midurethral sling (RMUS) may be considered for minimally mobile urethras, but should be used with caution 1
Urethral bulking agents are effective alternatives, though patients should be counseled about the potential need for repeat injections due to higher recurrence rates 1
Transobturator midurethral slings (TMUS) should be avoided in patients with fixed urethras as they may require additional tension, which increases complication risks 1
Synthetic mesh slings should be avoided in patients with poor tissue quality, significant scarring, or history of radiation therapy 1, 2

The World Journal of Emergency Surgery recommends obtaining urinary drainage as soon as possible via urethral or suprapubic catheter for traumatic injuries 3, 4
For traumatic injuries, perform urethrography every two weeks to monitor healing progress 3
In blunt posterior urethral injuries, initial conservative treatment with planned delayed surgical management is recommended 3, 5
When posterior urethral injury is associated with complex pelvic fracture, definitive surgical treatment with urethroplasty should be performed after healing of pelvic ring injury 6
For blunt posterior urethral injuries, immediate endoscopic realignment is preferred over immediate urethroplasty in hemodynamically stable patients 7
When endoscopic realignment fails, suprapubic catheter placement and delayed urethroplasty (preferably within 14 days) are indicated 7

Avoid placing synthetic mesh slings if the urethra was inadvertently injured during a procedure, or if the patient is undergoing concomitant urethral diverticulectomy, repair of urethrovaginal fistula, or urethral mesh excision 1, 2
Avoid placing synthetic mesh slings in patients with risk factors for poor wound healing (radiation therapy history, significant scarring, poor tissue quality) 1, 8
For urethral injuries, uretroscopy or uretrogram are the methods of choice for follow-up 6
Return to sport activities should be allowed only after microscopic hematuria is resolved 6
Placing excessive tension on synthetic slings in patients with fixed urethras increases the risk of complications 1

The European Association of Urology recommends an artificial urinary sphincter (AUS) or autologous fascial sling (AFS) as the most appropriate treatment option for patients with significant scarring and complete immobility of the urethra, providing circumferential compression and support without excessive tension 9, 10
An AUS is considered the gold standard for management of severe incontinence with a fixed urethra, and is most appropriate for patients with significant scarring and complete immobility of the urethra, according to the European Urology guidelines 9, 10

The American College of Physicians suggests that pelvic floor muscle training may provide modest benefit as an adjunct to other treatments for fixed urethral incontinence, although its effectiveness as a standalone treatment is limited 11

A 57-year-old female patient has been diagnosed with cystocele, midline (N81.11), rectocele (N81.6), and stress urinary incontinence (N39.3) 12, 13
The patient has failed conservative management, including a documented trial of pelvic floor exercises and physical therapy with limited success, and has a high burden on quality of life due to leaks requiring changing clothes 12, 13
The patient has stage 2 pelvic organ prolapse 13

The patient has documented stress urinary incontinence that is refractory to conservative management, meeting Aetna's medical necessity criteria for periurethral injections of bulking agents 12, 13
Bulkamid (polyacrylamide hydrogel) is FDA-approved for urinary incontinence 12
The patient's diagnosis code N39.3 (stress incontinence) is specifically listed as covered under the policy 12

The American Urological Association (AUA) recommends urethral bulking agents for patients with stress incontinence and a fixed/immobile urethra 12
The CPT/HCPCS Code for Bulkamid is L8606, a synthetic implant urinary 1ML 12
Success rates are generally lower than with midurethral slings but with fewer complications 12